Crotamine

• Description :

  Crotamine is a Na+ channel modulator. Crotamine is a 42 amino acid toxin cross-linked by three disulfide bridges. Crotamine has analgesic activity. Crotamine also interacts with lipid membranes and shows myonecrotic activity. Crotamine can be isolated from Crotalus durissus terrificus venom[1][2].

• UNSPSC :

  12352209

• Target :

  Sodium Channel

• Type :

  Peptides

• Related Pathways :

  Membrane Transporter/Ion Channel

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/crotamine.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSSC[C@@H]1NC2=O)C(N[C@@H](CC3=CNC=N3)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(NCC(NCC(N[C@@H](CC4=CNC=N4)C(N[C@@H](CSSC[C@@H](C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC5=CNC6=CC=CC=C56)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC7=CNC8=CC=CC=C78)C(N[C@H]2CCCCN)=O)=O)=O)=O)=O)NC9=O)C(N[C@@H](CC%10=CC=CC=C%10)C(N%11[C@@H](CCC%11)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CSSC[C@@H](C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CO)C(NCC(O)=O)=O)=O)=O)=O)=O)NC1=O)C(N[C@@H](CC(C)C)C(N%12[C@@H](CCC%12)C(N%13[C@@H](CCC%13)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%14=CC=CC=C%14)C(NCC(N[C@@H](CCCCN)C(N[C@@H](CCSC)C(N[C@H]9CC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC%15=CC=C(C=C%15)O)N

• Molecular Formula :

  C214H326N64O54S7

• Molecular Weight :

  4883.73

• References & Citations :

  [1]Nicastro G, et al. Solution structure of crotamine, a Na+ channel affecting toxin from Crotalus durissus terrificus venom. Eur J Biochem. 2003 May;270 (9) :1969-79.|[2]Kerkis I, et al. Biological versatility of crotamine--a cationic peptide from the venom of a South American rattlesnake. Expert Opin Investig Drugs. 2010 Dec;19 (12) :1515-25.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Peptides

• Clinical Information :

  No Development Reported